The decreased expression of CD3 ζ chains in cancer patients is not reversed BY IL‐2 Administration

Publisher Website
Google Scholar
Abstract
The mechanisms underlying the impaired immune response frequently observed in cancer patients are poorly understood. Recently, a decreased expression of the signal‐transducing CD3 ζ chains has been shown to occur in patients with colorectal or renal‐cell carcinoma. Here, we have investigated the expression of the ζ molecule on lymphocytes from patients with advanced cancers including renal‐cell carcinoma (n = 21), hepatic colorectal carcinoma metastases (n = 6), head‐and‐neck squamouscell carcinoma (n = 7) or miscellaneous tumors (n = 7), using flow cytometry analysis of PBMCs with monoclonal antibody specific for the cytoplasmic domain of the ζ chain. The same analysis was also performed with patients undergoing IL‐2 therapy (from 5 days up to 3 months i.v. or s.c). PBMCs from patients (n = 41) showed a significant decrease in expression of the ζ chains as compared to the levels found in lymphocytes from healthy controls (n = 15), which was not reversed by IL‐2 administration. Together, these results suggest that an alteration in the expression of the ζ‐chain‐transducing element in PBMCs may be a common cause of progressive immunosuppression in advanced cancer patients and that IL‐2 is not sufficient to reverse this situation in vivo.